A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
ConditionLichen Planopilaris
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorPriovant Therapeutics, Inc.
About this trial
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Eligibility criteria
Qualifiers
Age ≥ 18 years
Scalp biopsy consistent with LPP
Active and symptomatic LPP at screening and baseline-
Weight > 40 kg to < 130 kg with BMI ≤ 45 kg/m2
Disqualifiers
History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
High risk of thrombosis or cardiovascular disease
High risk of herpes zoster
Active or recent infection
Trial design
Treatments tested in this trial
- Oral Brepocitinib
- Placebo
Treatment groups
342 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov